• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 15, 2015

View Archived Issues

Atara confronts ‘the difficult questions,’ axes PINTA 745 after phase II failure

Atara Biotherapeutics Inc. is suspending development of PINTA 745 after the peptide-antibody combination missed its primary endpoint, defined as percent change from baseline in lean body mass as measured by dual energy X-ray absorptiometry at week 12, in a phase II proof-of-concept study. Read More

Akebia signs MTPC to Asia partnership; EU deal, phase III up next

Akebia Therapeutics Inc.’s president and CEO, John Butler, told investors during a Monday conference call that it was the company’s goal to find a Japanese partner for phase III-ready vadadustat, an oral therapy for the treatment of anemia related to chronic kidney disease (CKD), by the end of 2015. Read More

Novartis backs Seventure’s €160M venture fund targeting gut microbiome

DUBLIN – Seventure Partners has added Novartis AG as an investor in a new closing of its Health for Life Capital fund, taking the total to €160 million (US$175 million). It’s further evidence that big pharma is taking this emerging sector seriously. Read More

Fosun chairman may be snared in corruption investigation in China

HONG KONG – The chill of a wide-ranging anti-corruption campaign in China that has led to some very high-profile arrests spread with news that Guo Guangchang, the chairman of Fosun International Ltd., may have been snared in a corruption investigation. Shares of its subsidiary, Fosun Pharmaceutical Group Co. Ltd. (HKEX:2196, SS:600196), plunged more than 12 percent Monday on the Hong Kong stock exchange and about 4 percent in Shanghai. Read More

Pharnext moves PXT-3003 into phase III in Charcot-Marie-Tooth

DUBLIN – Pharnext SAS is embarking on a pivotal phase III trial of its lead drug cocktail, PXT-3003, in patients with the inherited progressive neuromuscular disorder Charcot-Marie-Tooth disease type 1A. Read More

Salford COPD, asthma study will use real-world design in phase III trial

LONDON – The question of to what extent those who meet the inclusion criteria in randomized controlled trials (RCTs) match the likely patient population is nowhere more marked than in respiratory diseases. Read More

Wuxi returns home and goes private for $3.3B

SHANGHAI – Wuxi Pharmatech (Cayman) Inc., a new breed of contract R&D organization, has completed the privatization process, requesting its stocks to stop trading on the New York Stock Exchange on Dec. 10. Wuxi’s chairman and chief executive, Ge Li, along with a consortium of private-equity investors paid $3.3 billion in cash to complete the deal. Wuxi first listed in the U.S. in 2007. Read More

Financings

Aeterna Zentaris Inc., of Quebec City, closed a previously announced underwritten public offering of 3 million common shares and warrants to acquire 2.1 million common shares with a combined purchase price of $5.55 for one common share together with a warrant to purchase 0.7 of a common share, generating net proceeds of approximately $15 million. Read More

Stock movers

Read More

Other news to note

Dimerix Ltd., of Melbourne, Australia, said the FDA granted orphan designation to propagermanium and irbesartan, the constituent parts of its drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis (FSGS), a leading cause of chronic kidney disease. Read More

In the clinic

Aequus Pharmaceuticals Inc., of Vancouver, British Columbia, completed dosing in the first stage of its phase I trial for the once-weekly transdermal aripiprazole patch, AQS1301. This study is the first in a two-stage phase I proof-of-concept program designed to assess the rate of absorption and to evaluate the profile of drug delivery over a seven-day period with Aequus’ transdermal formulation in 12 healthy volunteers. Results are expected to be announced early in 2016. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe